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ABSTRACT (237/250 words) 
 
PURPOSE: To use spectral-domain optical coherence tomography (SD-OCT) to 
evaluate macular hole surgery outcomes and features predicting anatomical 
failure. 
DESIGN: Retrospective interventional case series. 
METHODS: Fifty-two eyes of 50 consecutive patients with macular holes were 
examined. All eyes underwent 3-port pars plana vitrectomy with internal limiting 
membrane peeling. Eyes were examined postoperatively by dense serial 
SD-OCT scanning over the macula. 
RESULTS: Eyes with initial anatomical failure were significantly more likely to 
have greater axial length and refractive error and more posterior staphyloma 
compared to eyes with initial anatomical success (P = 0.031−0.0060, <0.0001). 
Overall initial and final anatomical success rates were 92.3% (48 of 52 eyes). In 
highly myopic eyes with axial lengths ≥ 26.0 mm, initial and final success rates 
were 73.3% (11 of 15 eyes) compared to 100.0% (37 of 37 eyes) of eyes with 
axial lengths < 26.0 mm (P = 0.0050). In highly myopic eyes, initial and final 
success rates were 0% (0 of 3 eyes) of eyes with axial lengths ≥ 30.0 mm 
compared to 91.7% (11 of 12 eyes) of eyes with axial lengths ≥ 26.0 mm and < 
30.0 mm (P < 0.0001). “Retinoschisis-like” thickening of the outer retina was 
seen in 3 (75.0%) of 4 eyes with initial failure compared to 3 (6.3%) of 48 eyes 
with initial success (P = 0.0030). 
CONCLUSIONS: Axial length ≥ 30.0 mm may increase the risk of anatomical 
failure of macular hole surgery. 
 
Abstract
July 6, 2010 
 
Thomas J. Liesegang, MD 
Editor-in-Chief 
American Journal of Ophthalmology 
Mayo Clinic 
4500 San Pablo Road 
Jacksonville, FL 32224-1865 
USA 
 
Re: AJO-10-155, "Axial Length and Outcomes of Macular Hole Surgery 
Assessed by Spectral-Domain Optical Coherence Tomography” 
 
Dear Dr. Liesegang: 
 
We thank you for reviewing our manuscript and for forwarding the enlightening 
comments. We appreciate the constructive suggestions of the reviewers and the 
Editor; these suggestions have helped us revise our manuscript. After carefully 
considering all of the raised points, we have revised our manuscript accordingly. 
We believe that we have addressed all of the comments, as mentioned in the list 
below. I attest that all coauthors of this manuscript (Kenji Suda, Masanori Hangai, 
and Nagahisa Yoshihisa) have seen and agree with all the changes made to the 
manuscript. We hope that you will find our revised manuscript suitable for 





Masanori Hangai, MD 
Associate Professor 
Department of Ophthalmology and Visual Sciences 
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【Comment #1】  
A problem is the analysis of the data. The statistical analysis and grouping of the 
results needs to be significantly revised. From Table 3 and Figure 1, it appears 
that 100% of patients with axial length of 30 mm or higher had macular holes that 
failed to close. These patients appear to be clearly different from the rest of the 
group.  
 
【Response to Comment #1】 
Thank you for the enlightening comment.   
We agree that we need to revise the statistical analysis and grouping of the 
results because all eyes with axial lengths ≥ 30 mm had macular holes that failed 
to close after surgery. In the revised manuscript, we have divided the highly 
myopic eyes with axial length ≥ 26 mm into eyes with axial lengths ≥ 30 mm 
(Group 1) and eyes with axial lengths 26−30 mm (Group 2) and then performed 
statistical analyses (Kruskal Wallis H-test for continuous data and Fisher’s exact 
test for categorical data) as shown in the revised Table 1. As a result, all eyes 
with axial lengths <26 mm had macular holes that successfully closed after the 
initial surgery, 91.7% of eyes with axial lengths 26−30 mm had macular holes 
that successfully closed after the initial surgery, and no eyes with axial lengths ≥ 
30 mm had macular holes that successfully closed after the initial surgery. As 
suggested, this grouping successfully shows that the eyes with axial lengths ≥ 
30 mm are clearly different from the other groups. 
 According to this grouping by axial length, we have revised Table 1 and 
the corresponding descriptions in the Results section of the revised manuscript 
(page 3, line 50−page 4, line 39; page 5, lines 37−40), and revised the Results 
section of the abstract. Here, we have re-arranged the order of data presentation 
as follows: 
 
1. We have presented factors associated with initial success or initial failure of 
macular hole surgery prior to the presentation of outcomes and factors of macular 
hole surgery according to axial length with a new subheading, “Factors Associated 
with Initial Failure of Macular Hole Surgery” (page 3, lines 40−46 of the revised 
manuscript). Accordingly, we have re-numbered Table 2→Table 1 and Table 
1→Table 2. 
2. We presented Figure 1 and then revised grouping of the study eyes into 3 groups 
based on axial length. These were addressed in the paragraph with a new 
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subheading, “Grouping According to Axial Length” (page 3, lines 50−Page 4, line 38 
of the revised manuscript). 
 
We have left the values for eyes with axial lengths ≥ 26 mm (Group 1 + Group 2) 
because this appears to be a useful way to compare our results with those of 
other studies, which did not divide eyes with high myopia into 2 groups. We 
then conducted statistical analysis among the 3 groups as shown in the revised 
Table 1. According to the revision of the grouping of the statistical analysis and 
the results, we have extensively revised the Discussion section of the revised 




【Comment #2】  
Only 2 other patients in the entire series failed to close. One of them apparently 
had symptoms for 10 years. Macular holes of that duration have poor success 
rates, and this patient may be different enough that he should be left out of the 
study. The one remaining failure was a moderate myope with symptoms duration 
of "NA". It makes little sense to combine the moderate myopes with the high 
myopes based on this one failure. 
 
【Response to Comment #2】 
We agree that we should remove the eye that had symptoms for 10 years and 
that moderate myopes and high myopes should not be combined based on the 
failure of this eye. We have removed that eye from the analysis and changed the 
axial length grouping so that moderate myopes and the high myopes are divided 
as addressed in the Response to Comment #1. According to the exclusion, we 
have revised Table 1 (Group 3, Emmetropia/Mild Myopia/Hyperopia) and Table 
2 (Initial Failure group) and the corresponding descriptions throughout the 
Results section (page 3, lines 32−37, 45−47, 51−54, 56, and 36; page 4, line 19, 
line 50, lines 56−58; page 5, lines 30−32), the Methods section (page 1, lines 
54−56, and 33, page 2, lines 43−45), and Figure 1. 
 
After we removed the eye that had symptoms for 10 years, we lost the statistical 
difference between any factors in multiple logistic regression analysis, so we 
removed the description related to multiple logistic regression analysis from the 
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Methods, Results, and Discussion sections. We believe that, since the main 
finding of our study is that 75% of eyes with unsuccessful macular hole closure 
had axial lengths ≥ 30.0 mm (100% of patients with axial lengths ≥ 30 mm had 
macular holes that failed to close) as pointed out by Comment #1, this removal 
does not critically change our manuscript.   
 
In addition, differences in mean macular hole sizes have lost statistical 
significance as shown in the revised Table 2. 
 
【Comment #3】  
A conclusion from the data is that extremely long eyes (greater than 30 mm) have 
poor success rates. For patients with duration of symptoms less than 1 year, and 
axial length of 29 mm or less, the success rate is close to or at 100 percent. To 
draw any other conclusion would require a much larger number of patients. 
Combining the moderate myopia group with the high myopia group confuses the 
picture, and is not supported by the data. 
 
【Response to Comment #3】 
We agree that a conclusion from our data is that extremely long eyes (≥30 mm) 
have poor success rates. We have extensively revised our manuscript based on 
dividing highly myopic eyes with axial length ≥ 26 mm into eyes with axial 
lengths ≥ 30 mm (Group 1) and eyes with axial lengths 26−30 mm (Group 2) as 
addressed in the response to Comment #1. We then revised the conclusion in 
the last paragraph of the Discussion section of the revised manuscript (page 7, 
lines 45−51) and the Conclusion section of the revised abstract. 
 
【Comment #4】The finding of retinoschisis-like patterns in the OCTs is 
interesting. It may indicate differences in tractional forces in some patients who 
develop macular holes. Since many of these patients have high myopia, the axial 
length of the eye may play a role in the development of this pattern. This pattern 
may also be predictive of a lower success rate, but exploration of this point would 
require a larger number of patients. 
 
【Response to Comment #4】 
Thank you for the comments with regard to the potential role of retinoschisis-like 
patterns in the OCTs in a lower success rate. We agree that we need a larger 
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number of patients to explore the predictive role of this feature in macular hole 
surgical failure. On the other hand, too much discussion on retinoschisis-like 
patterns was pointed out by Comment #7. According to these comments, we 
have revised the fourth, fifth, and sixth paragraphs of the original manuscript into 
the fourth and fifth paragraphs of the revised manuscript (page 6, lines 48− Page 
7, line 15). Here, we have simplified the discussion so that the clinical 
significance of this feature is clearly addressed without too much discussion. We 
have also added sentences to point out the sample size limitation (page 7, lines 
8−10, and 15). We believe these revisions appropriately respond to Comment #4 
as well as to Comment #7. 
 
【Comment #5】 A critical error in the paper is on page four, line one in which 
they state that the surgery is successful on eleven of thirteen eyes (=73%). This is 
actually eleven of fifteen eyes (in thirteen patients). As they have stated it the 
data would not be statistically significant. The duration of follow-up is not noted. It 
apparently is relatively long since visions have recovered to a good level in many 
of the patients. 
 
【Response to Comment #5】 
We apologize for the error in which the number of patients was shown instead of 
that of eyes. We have corrected the error on page 4, line 24 of the revised 
manuscript and on line 6 of the Results section of the revised abstract.   
 
We are sorry that we did not describe the follow-up duration for visual acuity 
after surgery we used in our original manuscript. We used visual acuity at 6 
months after the last surgery. We have added this description to the Results 
section (page 4, line 34 of the revised manuscript) and to Tables 1 and 2. 
 
 
【Comment #6】The authors state that they did multiple regression analysis and 
found no other factor except actual length with correlated with closure of the 
holes. However, one table indicates that duration of symptoms was 37.5 months 
in patients with initial failure in the non-closure group versus 3.1 months in 
patients with initial success in the closure group. It seems that this should be 
statistically significant depending on how the data is analyzed.  
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【Response to Comment #6】 
As suggested in Comment #2, we have removed the eye that had symptoms for 
10 years. We then re-calculated multiple logistic regression, and consequently 
found no factors that correlate with macular hole closure. Therefore, we have 
removed the description related to multiple logistic regression analysis from the 
Methods, Results, and Discussion sections as addressed in the response to 
Comment #2. We believe that, since the main finding of our study is that 75% of 
eyes with unsuccessful macular hole closure had axial lengths ≥ 30.0 mm (100% 
of patients with axial lengths ≥ 30 mm had macular holes that failed to close) as 
pointed out by Comment #1, this removal does not critically change our 
manuscript. 
  
After we removed the eye in question, there were still significant preoperative 
differences between eyes with initial success and failure in mean axial length 
and whether there was posterior staphyloma but not in macular hole size. 
Refractive error became a significantly different factor between groups. These 
changes were incorporated into the Results section of the revised manuscript 
(page 3, lines 40−46), the revised abstract, and Table 1. 
 
【Comment #7】There is a great deal of discussion about "retinoschisis like 
features". The authors are describing the generalized thickening of the retina 
which involves the outer retinal layers. Since the duration of symptoms is longer 
in patients with failure it may be that this finding correlates with duration rather 
than having a pathogenic meaning. Do not believe that the description of the 
retinoschisis like feature, an analysis of its assocation, or speculation on its 
causality is useful to the paper.  
It may indicate differences in tractional forces in some patients who develop 
macular holes. Since many of these patients have high myopia, the axial length of 
the eye may play a role in the development of this pattern. This pattern may also 
be predictive of a lower success rate, but exploration of this point would require a 
larger number of patients. 
 
【Response to Comment #7】 
We agree we included some inessential information regarding "retinoschisis-like” 
features. It is uncertain whether this finding correlates with axial length or 
symptom duration because symptom duration is also longer in eyes with failure 
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than eyes with success, although this difference was not statistically significant. 
We believe it has some meaning to point out the presence of this feature 
because it is possible that this feature may be associated with tractional forces in 
some patients who develop macular holes, longer axial length, and lower surgical 
success rate, as suggested in Comment #4. In particular, higher resolution 
images created with enhanced SD-OCT may have been useful to visualize this 
features that had not been previously reported in eyes with macular holes. 
However, in order to discuss the significance of this feature in the pathogenesis 
of macular holes in eyes with high myopia and the surgical outcome of macular 
hole surgery, we would need a larger number of patients as pointed out by 
Comment #4. 
 
We have tried to just put emphasis on the presence of the "retinoschisis-like” 
features and have weakened our speculation of the role of this feature. We have 
removed much of the discussion regarding the comparison with macular 
retinoschisis (fourth paragraph of the original manuscript). We have also 
removed much of the discussion about the comparison of macular morphologies 
of highly myopic eyes with macular holes with those of typical idiopathic macular 
holes (fifth paragraph of the original manuscript). Consequently, we have just 
addressed that the "retinoschisis-like” features were found in some eyes, 
particularly in eyes with failure, and in eyes with severely high myopia (axial 
lengths ≥ 30.0 mm). We have only pointed out the possibility that this feature 
may be associated with axial length and anatomical failure of macular hole 
surgeries. We did not point out the other possibility that this feature may be 
associated with symptom durations because we did not obtain statistical 
differences in symptom duration between eyes with failure and those with 
success. Finally, we concluded that we need a larger number of patients in order 
to confirm these speculations.   
 
In summary, we have revised the fourth, fifth, and sixth paragraphs of the 
original manuscript into the fourth and fifth paragraphs of the revised manuscript.   
 
We have not largely changed the seventh paragraph of the original manuscript 
that addressed speculations about possible remaining traction as a cause of 
anatomical failure of macular hole surgeries. Our main findings were that 
macular hole closure was unsuccessful in all highly myopic eyes with axial 
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lengths ≥ 30.0 mm and our sub-findings were that eyes with initial anatomical 
failure were significantly more likely to have greater axial length, more posterior 
staphyloma, and more “retinoschisis-like” features compared to eyes with initial 
anatomical success. Readers will consider the reason why macular hole closure 
was unsuccessful in all highly myopic eyes with axial lengths ≥ 30.0 mm. 
Although our results did not provide strong evidence to answer to this question, 
our description of the speculative mechanisms underlining our finding would help 
to the readers’ considerations. 
 
We believe these revisions appropriately responded to both Comment #7 and 
Comment #4 (page 6, lines 48− Page 7, line 15 of the revised manuscript) and 




The paper could be considerably shortened. 
 
【Response to Comment #8】 
We have tried to shorten the manuscript throughout. The total word count of the 
text has been reduced from 3,765 to 3,098. 
 
The main deletions are as follows: 
 
First, we have considerably shortened the fourth−sixth paragraphs of the 
Discussion section to respond to the above comments, particularly Comment #4 
and Comment #7. 
 
We have removed the first and third sentences of the paragraph subtitled 
“Posterior Staphyloma” (page 4, line 58−page 5, line 10 in the original 
manuscript). The first sentence has been removed because the same result was 
described in the page 3, lines 45−47 of the revised manuscript. The third 
sentence was removed because it does not appear to be useful for comparing 
eyes with retinoschisis-like features with or without posterior staphyloma in our 
small patient number.  
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We have removed “The information collected retrospectively from each of the 
medical records included patient age and gender, duration of symptoms due to 
macular holes, axial length, preoperative refractive errors, preoperative and 
postoperative BCVA, size and stage of macular holes, presence or absence of 
posterior staphyloma, and surgical procedure.” from the Methods section of the 
original manuscript (page 2, lines 23−31) because this data is shown in the 
Tables. 
 
We have removed the phrases “The study was approved by the Institutional 
Review Board and Ethics Committee of Kyoto University Graduate School of 
Medicine. Informed consent was obtained from all patients.” from the top of the 
Methods section of the original manuscript because these should be addressed 
in the Acknowledgments section. We have moved “All investigations adhered to 
the tenets of the Declaration of Helsinki.” to the Acknowledgments section. 
 
We have changed the description of axial lengths using symbols; ex. “axial 




The AJO uses the AMA Style for references, which now included journal issue 
numbers. 
 
【Response to Comment #9】 
We have included journal issue numbers for all the references according to the 




For each revision, the corresponding author must provide a statement that each 
of the coauthors has seen and agrees with each of the changes made to this 
manuscript in the revision and to the way his or her name is listed. It is not 
appropriate to add or remove authors at any time. Authors should only list their 
institutional affiliation at the time that they participated in the research; the 
corresponding author should additionally list his/her current address and email 
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for future correspondence.  
 
【Response to Comment #10】 
I, the corresponding author, have confirmed that all co-authors of this manuscript 
(Kenji Suda, Masanori Hangai, and Nagahisa Yoshihisa) have seen and agree 




Please ensure that all files intended for final publication are submitted to the 
office with each revision. If your final revision does not include all necessary files, 
those files will not be transmitted for publication. A common, and unacceptable, 
deficiency of many submissions is failure to refer to (call out) each figure, table 
and reference in the text. Please confirm that you have checked this function.  
 
【Response to Comment #11】 
We have submitted all files intended for final publication to the office in this 





Only one abstract should appear in your submission. Please make sure the 
corrected abstract is uploaded separately from the text and remove any extra 
copies of the abstract from the manuscript file. Please correct the Abstract if 
meaningful changes were made in the text during revision process. 
 
【Response to Comment #12】 
We have uploaded the corrected abstract separately from the text. We corrected 
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The title page should also contain a suggested "short title" (limited to 45 
characters) for your manuscript that will be included as footnote in the printed 
version. See the print journal for examples.  
 
【Response to Comment #13】 




The Journal requires that Clinical Trials be registered and the Acknowledgement 
Section should contain a statement about the registration location and number. 
Satisfactory public databases include the National Institute of Health maintained 
site at http://www.clinicaltrials.gov (for either NIH or non-NIH sponsored studies) 
or the International Standard Randomized Controlled Trials at 
http://www.controlled-trials.com. 
 
【Response to Comment #14】 




For all human studies, please confirm that the Institutional Review Board (or 
similar body) statement and the Informed Consent statement for research is 
within the Acknowledgement section (see below). The authors are requested to 
confirm that they are in compliance with their Institutional Review Boards (IRBs) 
or similar authorities and HIPAA requirements; some IRBs require approval for 
even single case reports. In general, authors should not make the decision 
whether IRB approval is required; their IRB should make that determination. For 
animal studies, please confirm that the statement regarding the care of animals is 
within the Acknowledgement section. If this is a systematic evaluation of a 
treatment or a device ("research"), then IRB approval is required usually in a 
prospective manner. The AJO will not publish research on humans that does not 
have IRB approval. For clarification, see: 
http://www.ijo.in/text.asp?2007/55/1/1/29486 
 
【Response to Comment #15】 
 
Axial length and macular hole surgery. Suda K, et al.—Page 11 
In the Acknowledgments section, we have stated that the Institutional Review 
Board approved this study and that an informed consent statement was 
obtained. We have also added a statement of adherence to the Declaration of 
Helsinki and all federal regulations in the Statement about Conformity with 




The AJO requires enhanced disclosure information from the authors in a specific 
format. The following information should appear, in the order indicated (labeled A 
through E), in the Acknowledgement section of the manuscript (just prior to the 
References). The information will appear in the print journal. This information 
should not appear on the Title page of the manuscript or in the Methods section of 
the manuscript. 
a. Funding/Support (including none): any government and non-government 
support must be acknowledged. (The authors are reminded that several 
governments require providing open access to your manuscript.)  
b. Financial Disclosures: now or in the previous two years that related to any 
commercial companies or devices (including none); employee, consultant or 
advisory positions; speaker bureaus, lecture fees; grant support, equity 
payments; patents; advisor to investment companies; and expert witness 
testimony. Financial involvement with companies that directly compete with 
products in this manuscript must also be disclosed. Do not try to determine 
yourself if your financial disclosures relate to the manuscript as that is for the 
editors and reader to determine.  
c. Contributions to Authors in each of these areas: design and conduct of the 
study; collection, management, analysis, and interpretation of the data; and 
preparation, review, or approval of the manuscript. After each component, 
provide author initials in parentheses, SAMPLE: Contributions of Authors: Design 
of the study (AB, CD, EF); Conduct of the study (AB, EF, GH), etc. Each author 
must have a specific role in the manuscript. Overall management/supervision of a 
laboratory alone or a position of chairmanship alone does not constitute an 
authorship role. The AJO does not permit guest or honorary authorship.  
d. Statement about Conformity with Author Information: Name of IRB that 
approved the research or provide a statement and rationale as to why the named 
IRB waived approval, proper informed consent for both the treatment and 
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participation in the research, HIPAA compliance, Clinical Trials registration, 
number and location, and Institutional Animal Care and Use Committee 
guidelines. If the IRB waived the need for approval of this research, then indicate 
adherence to the Declaration of Helsinki and all federal or state laws in your 
country. Authors cannot make the decision as to whether IRB approval is 
needed; your IRB should make that decision and provide a waiver if they feel it 
does not require IRB approval.  
e. Other Acknowledgments: Statisticians and medical writers or industry writers 
might fulfill the criteria for authorship and should be recognized in that role. 
Otherwise, recognize statistical consultation, medical writers or industry writers in 
the acknowledgment. Include the name and affiliation of the individual. The AJO 
does not accept manuscripts that do not accurately reflect who wrote the content 
i.e., the AJO does not permit ghost (hidden) authors. Editorial assistants, 
photographers, artists, laboratory associates, and others who simply assist in 
preparation of a manuscript are not to be acknowledged, however valuable their 
service. The Editor-in-Chief will permit limited exceptions. Because readers may 
infer endorsement of the data and conclusions, all persons must have given 
permission to be acknowledged and this must be confirmed in the cover letter. 
 
【Response to Comment #16】 
We have disclosed all of the required information in the Acknowledgements 
section and added a description of adherence to the Declaration of Helsinki and 
all federal regulations in the Statement about Conformity with Author Information 




FIGURE USAGE: The AJO's manuscript submission process is now an entirely 
digital process. Our system has an Artwork Quality Check function which will 
check your figures at the time of revision. Once the File Upload page is complete, 
click Next to run Artwork QC, which will provide results according to our 
print-quality guidelines. Simply click on the results to obtain feedback explaining 
any shortcomings on the figures and how to fix the problems. Authors should 
bear in mind, however, that the AJO standards for art as listed in the Author 
Instructions exceed those of this rudimentary artwork quality check tool and the 
authors are required to adhere to Author Information at AJO.com, despite 
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assurances from this Artwork Quality Check. Please make all improvements prior 
to resubmission. The AJO Author Instructions has specific information regarding 
figure requirements, available at AJO.com. 
 
【Response to Comment #17】 




For multi-part figures, each part of the figure should be submitted individually at 
the correct resolution and file type, labeled according to AJO style. You may 
additionally submit a composite figure in Word to indicate how you would wish the 
individual figure parts to be arranged upon publication. Please note that due to 
space restrictions, the publisher may not be able to use the provided layout, so it 
is imperative to also include any arrows, markings, and labels on the 
individually-submitted figures while maintaining the correct resolution, size, and 
file format. Alternatively, you may submit a composite figure only, at the correct 
resolution above with any appropriate arrows, markings, or labels, though the 
publisher may later request individual files if space does not permit use of the 
collage and publication could be delayed as a result. 
 
【Response to Comment #18】 




If your manuscript was submitted with color figures, it is expected that the authors 
will pay for the color art that appears in the print issue. It is not appropriate to 
switch to black and white figures during a revision stage if the manuscript was 
peer reviewed with color figures. The Editor in Chief reserves the right to decide if 
Black and White figures are more appropriate in place of any color figures. See 
Author Information at AJO.com for more specific details concerning the costs. 
 
【Response to Comment #19】 
We will pay for the color art. 
 




REFERENCES: PLEASE NOTE that the AJO style is identical to the AMA style 
and lists the first 6 authors; if more than 6, then list the first 3 and then "et al." 
More information about AJO references is available in Author Information at 
AJO.com. At this revision stage, the Editor in Chief MAY REJECT a manuscript 
with incorrect AJO formatting of any of the references. The authors are SOLELY 
responsible for correct references; this service is not provided by the Journal 
copyeditors.  
 
【Response to Comment #20】 




The Corresponding Author is requested to provide a Table of Contents Statement 
(up to 75 words in length) that presents the content and clinical implications of the 
article for the Table of Contents of the Journal (see print copy of AJO). This 
statement should be on a separate page that contains the manuscript title and 
manuscript number. This is a stand-alone document from the manuscript and as 
such should not contain abbreviations or first-person pronouns (I, we).  
 
【Response to Comment #21】 




Please confirm that your Discussion Section adheres to the following Author 
Information at AJO.com as appropriate for your manuscript: "Elucidate (but do 
not reiterate) the results, identify any statistically or clinically significant limitations 
or qualifications of the study, provide responses to other and contradictory 
literature, and state the conclusions that are directly supported by the data. 
Excessive generalization and undue speculation should be avoided. Give equal 
emphasis to positive and negative findings, state whether and what additional 
study is required, and conclude with the clinical applications or implications 
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supported by the study. The conclusions are incorporated into the end of the 
discussion. Authors should avoid making statements on economic benefits and 
costs unless their manuscript includes economic data and analyses. Do not 
allude to work that has not been completed." 
 
【Response to Comment #22】 
We have confirmed that our Discussion section adheres to the Author 




AJO.com offers the opportunity to present additional data that cannot be 
published in the print issue, including additional illustrations and tables, 
videotapes of procedures, and animations. Supplemental Material must be 
submitted at the time of revision according to specifications, and such material 
may be edited. 
Instructions for preparing supplemental material are listed at 
www.ajo.com/authorinfo under the "Accepted Manuscripts" sections. When 
uploading your supplemental material on the Attach Files page, please choose 
Multimedia Supplementary Materials for all parts and label each part (eg., 
Supplemental Figure Legend, Supplemental Figure 1, Supplemental video etc.). 
The legend for all Supplemental Material should also be uploaded as Multimedia 
Supplementary Materials. Each figure legend or table title must contain enough 
information so as to be able to be understood independent of the manuscript text 
(stand alone). If you are including supplemental material with your submission, 
please note the following on your manuscript title page: "Supplemental Material 
available at AJO.com" and also note, at the appropriate location in the manuscript 
and in parenthesis, "(Supplemental Material at AJO.com or Supplemental Figure 
1)". 
Once the article is accepted, the Supplemental Material will be forwarded by the 
AJO office to Dr Kaiser, the AJO Associate Editor supervising the Supplemental 
Material at AJO.com. You will be notified of its acceptance or requests for 
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INTRODUCTION 
Based on the theory that vitreous traction is the cause of idiopathic macular holes,1-4 vitreoretinal 
surgery to relieve traction has become the established treatment and currently is highly 
successful for closing macular holes.5-10 In a pilot study reported in 1991, Kelly and Wendel5 
achieved a 58% success rate for anatomical closure of full-thickness macular holes using pars 
plana vitrectomy (PPV) with posterior hyaloid peeling and intraocular gas tamponade. For 
surgery in which internal limiting membrane (ILM) peeling was also performed, primary closure 
rates of 76.4% to 100% have been reported.11  
Shorter duration of symptoms, earlier stage or smaller size of the macular hole, better 
preoperative visual acuity, younger patient age, and male patient gender have been reported to 
be significantly associated with better surgical outcomes.7-9,12-18 However, consensus is lacking 
that high myopia/longer axial length is related to worse outcomes of macular hole surgery.19-22 
Patel, et al19 reported a relatively low (60%) closure rate for macular holes in highly myopic eyes, 
but in case-control studies, Sulkes, et al20 and Kobayashi, et al21 found no association between 
axial length and anatomical success of surgery. However, these studies did not use optical 
coherence tomography (OCT) to confirm closure of the macular hole, and it can be difficult to 
determine whether macular holes are closed by biomicroscopic examinations alone, especially in 
highly myopic eyes with choroidal atrophy, as shown by Coppe, et al,23 who detected macular 
holes by OCT in 24 of 383 (6.26%) asymptomatic myopic eyes. 
With more recently developed spectral-domain OCT (SD-OCT) technology, macular 
features can be visualized in great detail.24-27 Commercially available SD-OCT instruments 
acquire images 43 to 133 times faster than time-domain (Stratus) OCT instruments, which allows 
for acquisition of densely spaced serial B-scans that can be used to more precisely detect 
macular holes. High-speed image acquisition also allows averaging of multiple OCT B-scans at 
each location of interest on the retina, so as to reduce speckle noise and thus provide a detailed 
view of macular anatomy.28 In this study, we used SD-OCT to study the relationship between 





Patient data were obtained by retrospective review of the medical records of 49 consecutive 
patients (52 eyes) who underwent surgery for macular hole at Kyoto University Hospital between 
February 2006 and July 2008. Candidates for the study were identified by review of the authors' 
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presentation of macular hole; 2) treatment with conventional 20-gauge or 23-gauge three-port 
pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling; and 3) a follow-up 
period of more than six months from the last intraocular surgery. Eyes were excluded from the 
study if they had preexisting ocular diseases or a history of ocular surgery, except for cataract 
surgery. Other exclusion criteria included 1) a history of treatment for peripheral retinal breaks 
before and after the primary surgery or 2) macular hole with retinal detachment.  
All patients had undergone comprehensive ophthalmologic examinations before 
macular hole surgery, measurements of refractive errors (ARK-700A autorefractor, Nidek, 
Gamagori, Japan), measurements of uncorrected visual acuity (VA) and best-corrected visual 
acuity (BCVA) using the 5-meter Landolt chart, measurement of axial length using A-scan 
ultrasonography (UD-6000, TOMEY CORPORATION, Nagoya, Japan), slit-lamp examinations, 
measurements of intraocular pressure using a Goldmann applanation tonometer, and dilated 
indirect slit-lamp biomicroscopy.  
The size of each macular hole before surgery was measured with reference to the 
diameter (approximately 150 μm) of the vein on the edge of the optic disc.  
 Conventional 20-gauge three-port PPV was performed in 10 eyes and 23-gauge 
transconjunctival PPV was performed in the other 43 eyes. A posterior vitreous detachment was 
created, followed by removal of the residual thin premacular posterior cortex. The peripheral 
vitreous was also excised. Triamcinolone acetonide was used intraoperatively to facilitate 
visualization of the vitreous and posterior hyaloid in all of the eyes in this study.29 All of the eyes 
underwent ILM peeling (3 to 4 disc diameters in size) with an ILM forceps, after staining with 
indocyanine green (ICG) or triamcinolone acetonide.11,30 In all eyes, fluid-air exchange was 
performed, followed by gas tamponade (instillation of 40 ml of sulfur hexafluoride (SF6), 25%). 
Patients were instructed to keep the head prone (face downwards) for at least 1 week 
postoperatively. In the 46 of 52 eyes that were phakic before macular hole surgery, 
phacoemulsification was performed before PPV, with implantation of an intraocular lens in all 46 
eyes. 
 
Optical Coherence Tomography Examinations 
OCT examinations were performed by experienced ophthalmologists using time-domain OCT 
(Stratus) and/or SD-OCT (usually Spectralis™ HRA+OCT; Heidelberg Engineering, Heidelberg, 
Germany or occasionally RTVue-100; Optovue, Fremont, CA, USA). On preoperative scans of 
eyes with moderate cataract, time-domain (Stratus) OCT images tended to provide better 
information than SD-OCT scans.  
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after surgery, dense serial SD-OCT scans were obtained over the macula; scanning was usually 
horizontal but sometimes vertical or radial. Initial anatomical success was defined as no visible 
open macular hole on any serial SD-OCT B-scans during the first month after the first macular 
hole surgery. To identify possible abnormalities in retinal microanatomy, so-called 
speckle-noise-reduced images were generated by averaging 20 to 50 SD-OCT B-scans obtained 
at each location of interest on the retina.28  
 
Statistical Analyses 
Statistical analyses were performed using SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). The 
logarithm of the minimal angle of resolution (logMAR) was used for statistical analyses involving 
VA. For continuous values, the mean ± standard deviation (SD) was calculated for each group 
and differences between 2 groups and 3 groups were evaluated for statistical significance by the 
Mann–Whitney U-test and the Kruskal Wallis H-test followed by Dunnett’s rank test, respectively. 




Fifty-two eyes of 49 patients (18 men, 31 women) with macular holes were included in this study. 
The 49 patients were 63.4 ± 8.6 years old (range, 34 to 82 years) and the 52 eyes had a mean 
preoperative refractive error of -3.0 ± 5.2 diopters (D) (range, 4.4 to -18.5 D). The median 
preoperative BCVA (Snellen equivalent) for the 52 eyes was 20/80 (range, 20/500 to 20/25).  
 
Factors Associated with Initial Failure of Macular Hole Surgery 
Table 1 shows the pre- and postoperative characteristics of eyes in which the initial surgery was 
a success or failure. There were significant preoperative differences between the groups in mean 
axial length (P < 0.0001), refractive error (0.031) and whether there was posterior staphyloma (P 
= 0.0060).  
 
Grouping According to Axial Length 
Mean axial length for the 52 eyes (24.6 ± 2.4 mm; range, 21.1 to 31.9 mm) was negatively 
correlated with age (r = -0.447, P = 0.001; Figure 1) but positively correlated with refractive error 
(r = -0.715, P = 0.0001). Three (60%) of 5 eyes with initial surgical failure were "outliers" on the 
linear regression curve (Fig 1). All 3 eyes had axial lengths ≥ 30.0 mm. Accordingly, the 52 eyes 
were divided into 3 groups based on whether they had severely high myopia (Group 1), defined 
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and <30.0 mm (Group 2), or mild myopia, emmetropia, or hyperopia (Group 3), defined as an 
axial length < 26.0 mm (Table 2). Eyes were statistically significantly different among the 3 
groups in mean age at onset of macular holes, mean axial length, mean preoperative refractive 
error, and in terms of the existence of posterior staphyloma (all, P < 0.0001) but not significantly 
different in patient gender, laterality, stage or size of macular hole, duration of symptoms, or 
preoperative logMAR BCVA (Table 2). 
 
Anatomical and Functional Success According to Axial Length 
The overall initial and final anatomical success rates of the macular hole surgeries were both 
92.3% (48 of 52 eyes) (Table 2). The median final BCVA (Snellen equivalent) was 20/32 (range, 
20/500 to 20/12.5). In eyes with axial lengths < 26.0 mm, the initial and final success rates were 
both 100.0% (37 of 37 eyes), and in highly myopic eyes with axial lengths ≥ 26.0 mm, the initial 
and final success rates were both 73.3% (11 of 15 eyes); this difference was significantly 
different (both, P = 0.0050). In highly myopic eyes with axial lengths ≥ 30.0 mm, the initial and 
overall success rates were both 0% (0 of 3 eyes), whereas in highly myopic eyes with axial 
lengths ≥ 26.0 mm and <30.0 mm, the initial and final success rates were both 91.7% (11 of 12 
eyes). The initial and final success rates in eyes with axial lengths ≥ 30.0 mm were significantly 
lower than those in eyes with axial lengths ≥ 26.0 mm and <30.0 mm, and in eyes with axial 
lengths < 26.0 mm (P < 0.0001 for both) (Table 2). At 6 months after the last surgery, the mean 
change in LogMAR of BCVA in eyes with axial lengths ≥ 30.0 mm was also significantly smaller 
than those in eyes with axial lengths ≥ 26.0 mm and <30.0 mm (P = 0.015) and in eyes with axial 
lengths < 26.0 mm (P = 0.020) (Table 2).  
 
Spectral-Domain Optical Coherence Tomography Findings 
On SD-OCT images obtained preoperatively, almost all eyes with all stages of macular holes (2, 
3, or 4) had centrifugal elevation of the retina limited to the fovea and cystoid spaces in the Henle 
nerve fiber layer, and sometimes in the inner nuclear layer, in the fovea or just outside the fovea 
(Fig 2).31,32  
However, on preoperative SD-OCT images of 6 (11.5%) of the 52 eyes, a 
"retinoschisis-like" feature was seen, consisting of widespread thickening of the retina in the 
extrafoveal as well as foveal region (Figs 3 and 4). The thickening appeared to be located in the 
outer retina. The “retinoschisis-like” feature was seen in 3 (6.3%) of 48 eyes with initial success 
and 3 (75.0%) of 4 eyes with initial failure of macular hole surgery; this difference was statistically 
different (Table 1, P = 0.0030). This "retinoschisis-like" feature was found to be associated with 
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seen in 3 (75%) of the 4 eyes with initial failure, compared to only 1 (9.1%) of 11 eyes with initial 
success (Table 3); this difference was statistically different (P = 0.033).  
Unexpectedly, the “retinoschisis-like” feature was also seen after macular hole surgery 
(Fig 3). Among the 15 eyes with axial lengths ≥ 26.0 mm, 4 had a flat open macular hole (failure 
of initial macular hole surgery but no “retinoschisis-like” feature, Fig 3) immediately after surgery, 
but 3 of these 4 developed a “retinoschisis-like” feature between 1 and 4 months after surgery; 2 
of these 3 eyes had “retinoschisis-like” features before surgery (Table 3). A postoperative 
“retinoschisis-like” feature was also found in a significantly higher proportion of eyes with initial 
failure (3/4 eyes, 75%) than in eyes with initial success of surgery (1/11 eyes, 9.1%; P = 0.033).  
 
Posterior Staphyloma 
Among highly myopic eyes with axial lengths ≥ 26.0 mm, the difference in proportions with 
staphyloma and initial success (3 of 4 eyes) vs initial failure (3 of 11 eyes) was not statistically 
different (P = 0.24; Table 3).  
 
Reoperation 
A second operation was performed in 3 of 4 eyes with initial failure of macular hole surgery. Two 
of these 3 eyes had both posterior staphyloma and a “retinoschisis-like” feature, and retinal 
detachment occurred within the posterior staphyloma 1 to 2 months after the second surgery (Fig 
4); the retina successfully reattached in one case, but not in the other case, after this second 
surgery, although the macular holes remained open in both eyes. The other eye that was 
reoperated upon had an axial length ≥ 26.0 mm and <30.0 mm; the macular hole did not close 
after the second operation. No eye had reopening of the macular hole.  
 
DISCUSSION 
The main finding of our study was that macular hole closure was unsuccessful in all highly 
myopic eyes with axial lengths ≥ 30.0 mm. Previous studies reported on relationships between 
initial success in macular hole surgery and factors such as symptom duration, the size or stage 
of the macular holes, or patient age or gender.12-18 However, findings are not consistent. In our 
study, greater axial length, higher refractive error, and the presence of posterior staphyloma 
were significantly associated with initial failure. Here, posterior staphyloma was found in all 3 
eyes with axial lengths ≥ 30.0 mm and in the 4 successful eyes with axial lengths < 30.0 mm. 
Thus, the axial length ≥ 30.0 mm appears to be most associated with unsuccessful macular hole 
closure. 



































































Axial length and macular hole surgery. Suda K, et al.—Page 6 
 
previous studies in surgical closure rates in myopic eyes with macular holes.19-22 The 
percentages of study eyes with axial lengths ≥ 30.0 mm may have affected the surgical closure 
rates in myopic eyes in those studies. Patel, et al 19 reported a low rate of closure (60.0%) of 
macular holes in patients with myopia of 6 diopters or greater. Sulkes, et al20 and Kobayashi, et 
al21 reported comparable rates of macular hole closure for eyes with "low" versus "high" myopia 
(92% versus 81.0% and 92% versus 81.3%, respectively). However, the percentages of study 
eyes with axial lengths ≥ 30.0 mm were not described in these studies. Grucia-Arumi, et al23 
reported macular hole closure rate of 87.5% after surgery in eyes with high myopia (8 diopters or 
more). This study included 5 eyes (20.8%) with axial lengths ≥ 30.0 mm and a rates of macular 
hole closure of 80% in these eyes compared to 89.5% in highly myopic eyes with axial lengths 
27.1–29.1 mm. This result is not consistent with our study in terms of closure rates in highly 
myopic eyes with axial lengths ≥ 30.0 mm. In contrast, the closure rate (91.7%) of highly myopic 
eyes with axial lengths 26.0–30.0 mm in our study was not significantly low compared to the 
closure rate (100%) of eyes with axial lengths < 26.0 mm. This closure rate of highly myopic eyes 
with axial lengths 26.0–30.0 mm appears to be comparable with the closure rate (89.5%) of eyes 
with axial lengths 27.1–29.1 mm in the study by Grucia-Arumi, et al23. 
We should be careful when we compare our study with previous studies since subject 
inclusion in 3 of those 4 studies was made on the basis of refraction and not axial length. In 
addition, these previous studies differ from ours in that they did not include ILM peeling or use 
OCT to determine if the macular holes were closed. Especially in eyes with high myopia and 
chorioretinal atrophy, it is difficult to see on biomicroscopy examinations if the macular hole is 
actually closed. Serial B-scan imaging with SD-OCT over the macula24-27 can be expected to 
more precisely identify the presence of macular holes after surgeries in eyes with high myopia 
and chorioretinal atrophy, even when the macular hole is not evident on biomicroscopic 
examination as seen in Figure 4 of our study. It is possible that these differences in study design, 
particularly in the use of SD-OCT, warrant that our finding of axial length ≥ 30.0 mm is most 
associated with unsuccessful macular hole closure. 
We found "retinoschisis-like" thickening of the outer retina, particularly in eyes with high 
myopia. This feature resembles retinal thickening seen in myopic macular retinoschisis (or 
myopic foveoschisis) in that the separation is widely seen over the macula,33-36 but it is different 
from the typical tomographic features of idiopathic macular holes in which retinal thickening is 
limited to the vicinity of the fovea.37-42 However, the eyes in our study with this feature also had 
multiple cystoid spaces in the inner nuclear layer, which is a typical feature of macular hole but 
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The “retinoschisis-like” feature was seen in 67% of eyes with severely high myopia 
(axial lengths ≥ 30.0 mm) compared to 16.7% of eyes with moderately high myopia (axial lengths 
≥ 26.0 mm and <30.0 mm) and 5.4% of eyes with axial lengths < 26.0 mm. A larger number of 
patients are required to determine if axial length plays a role in the development of this pattern. 
This “retinoschisis-like” feature was significantly associated with anatomical failure of the 
macular hole surgery (75%) and is likely predictive of anatomical failure of macular hole surgery 
in highly myopic eyes. Exploration of this point would also require a larger number of patients. 
It is possible that some remaining traction after ILM peeling is responsible for the failed 
macular hole closure in eyes with axial lengths ≥ 30.0 mm. This is suggested by the persistence 
or recurrence of retinoschisis-like thickening of the outer retina after ILM peeling. Possible 
sources of traction on the retina include the vitreous cortex, axial elongation, posterior 
staphyloma, the ILM, and retinal vessels in eyes with high myopia.35,36,43-48 Traction by the ILM 
should have been relieved by ILM peeling.45,47,49,50 However, remaining ILM, particularly ILM on 
the retinal vessels,45 may cause some traction.51 In our study, we found posterior staphyloma in 
all 3 eyes with axial lengths ≥ 30.0 mm. In eyes with axial lengths≥ 26.0 mm, posterior 
staphyloma was seen in 3 (75%) of 4 eyes with failure compared to only 3 (27.3%) of 11 eyes 
with success, although this difference was not statistically significant. It is possible that, as with 
myopic macular retinoschisis,29 traction in the posterior direction caused by severe axial 
elongation plus posterior staphyloma is associated with greater likelihood of failures of macular 
hole surgery. Exploration of this point would also require a larger number of patients. 
A limitation of the current study is its retrospective design. We could not determine the 
actual extent of ILM peeling from chart reviews. In addition, serial B-scans on the same scan 
protocols were not available to allow us to determine whether the macular holes had closed. 
 In summary, our retrospective study found that in eyes with macular hole that were 
treated with PPV with ILM peeling and gas tamponade, initial or final closure of macular holes as 
confirmed by serial SD-OCT scans could not be achieved in any eyes with severely high myopia 
with axial lengths ≥ 30.0 mm. The closure rate of highly myopic eyes with axial lengths 26.0–30.0 
mm was not significantly lower than that of eyes with axial lengths < 26.0 mm. Further 
larger-scale investigations will be required to determine other prognostic factors in the surgical 
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FIGURE CAPTIONS 
Figure 1. Linear regression of axial length in millimeters (mm) against age (r = -0.447, P = 0.001) 
for 52 eyes with macular holes treated surgically. White circles = eyes in which the initial surgery 
was successful. Black circles = eyes in which the initial surgery failed to close the hole.  
 
Figure 2. Abnormal features in horizontal 9-mm-long B-scan images obtained by 
speckle-noise-reduced (averaging multiple B-scans at the same location) spectral-domain 
optical coherence tomography (left column, from top to bottom) in eyes with full-thickness 
macular holes and axial lengths < 26.0 mm. (Right column, from top to bottom) Color fundus 
photographs show, by green arrows, the direction of scanning to obtain images in (left column, 
from top to bottom), respectively. (Top) Stage 2 macular hole in the left eye of a 68-year-old 
man. (Middle) Stage 3 macular hole in the left eye of a 63-year-old woman. (Bottom) Stage 4 
macular hole in the left eye of a 65-year-old woman. Abnormal features, shown by asterisks and 
white arrows, were cystoid spaces in the Henle nerve fiber layer and the inner nuclear layer, 
respectively, that were seen only in the vicinity of the fovea, in all scans, and retinal thickening, 
also limited to the vicinity of the fovea (left column, from top to bottom).  
 
Figure 3. Images of the right eye of a 63-year-old woman with macular hole. Best-corrected 
visual acuity before surgery was 20/333 and axial length was 26.7 mm. (Top row left) A 
horizontal time-domain optical coherence tomography (OCT) B-scan obtained at the initial visit 
(Upper), and horizontal speckle-noise-reduced spectral-domain OCT images one month after 
the first operation (Lower). The image in (Top row left upper) is blurred, due to cataract, but 
shows a stage 4 full-thickness macular hole with apparent retinal thickening, mainly in the outer 
retina, that extends widely extrafoveally. (Top right) A color fundus photograph obtained one 
month after the first operation. The green (6-mm long) and white (9-mm long) arrows indicate the 
scan lines in (Top left) and in (Second row) and (Third row), respectively. (Second and third 
rows) Horizontal speckle-noise-reduced spectral-domain OCT images one year (Second row) 
after the first operation, and one month after the second surgery (Third row). One month after 
the first operation, the macular hole remained open but its edge was not elevated. At one year 
after the operation, the edge of the macular hole was lifted up and the retina was thickened over 
much of the macula. A second operation was therefore performed. One month after the second 
operation, the macular hole remained open and thickening of the retina in the macula persisted. 
(Bottom left and right), Magnified (2X) views of areas outlined by red dashed lines in the 
B-scan images in (Second row) and (Third row), respectively. Where the retina was thickened, 
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layer and the outer nuclear layer. The extent of the “retinoschisis-like” feature is indicated by 
white double-headed arrows. 
 
Figure 4. Images of the right eye of a 58-year-old woman with macular hole and posterior 
staphyloma. Best-corrected visual acuity before surgery was 20/125 and axial length was 31.89 
mm. (Left) Horizontal 9-mm-long speckle-noise-reduced spectral domain optical coherence 
tomography images. (Right) Color fundus photographs. (Top) Four months before the first 
operation; retinal thickening was limited to the nasal retina. (Second row) Two months before 
the first operation, retinal thickening extended widely in the macula and a “retinoschisis-like” 
feature became evident in the macular region (white double-headed arrows). (Third row) One 
month after the first operation, the macular hole and “retinoschisis-like” feature (white 
double-headed arrows) were still present and retinal detachment appeared to have extended. 
(Bottom) 2 months after the second operation the macular hole was larger, the nasal retina 
appeared to have shrunk, and temporal retinal detachment had enlarged, but the 
“retinoschisis-like” feature had disappeared. 
 
TABLE 1. Factors Associated with Initial Success or Initial Failure of Macular Hole Surgery 
 
Factor Initial Success Initial Failure P value All Eyes 
Number of eyes 48 4  52 
Patient age (n=50), years; 
mean ± SD (range) 
63.4 ± 8.9 
(34 – 82) 
63.0 ± 5.0 




Men/ Women 20/28 0/4 0.15 c 20/32 
Right eyes/Left eyes 25/23 3/1 0.62 c 28/24 
Axial length, mm 
mean ± SD (range) 
24.2 ± 1.87 
(21.1 – 28.1) 
30.0 ± 2.3 
(26.7 – 31.9) 
<0.0001 b 
24.6 
(21.1 – 31.9) 
Preop. refractive error, 
diopters 
mean ± SD (range) 
-2.36 ± 4.41 
(4.4 – -14.4) 
-10.3 ± 8.89 
(-2.5 – -18.5) 
0.031 b 
-3.0 ± 5.2 
(-18.5 – 4.4) 
Macular hole 
stage       
                              
II 13 0 0.67 c 13 
III 21 2  23 
IV 14 2  16 
Symptom duration, months 
mean ± SD (range) 
3.1 ± 2.6 
(0.5 – 12) 
10.0 ± 12.3 
(1 – 24) 
0.39 b 
3.5 ± 4.0 
(0.5 – 24) 
Size of hole, relative to 
"disc vein diameter" 
4.0 ± 1.6 
(1.2 – 9.7) 
5.8 ± 1.4 
(4.7 – 7.4) 
0.056 b 
4.1 ± 1.6 
(1.2 – 9.7) 
Preop. LogMAR BCVA 
mean ± SD (range) 
0.60 ± 0.33 
(0.046 – 1.40) 
0.89 ± 0.36 
(0.398 – 1.222) 
0.11 b 
0.62 ± 0.34 
(0.050 – 1.40) 
Postop. LogMAR BCVA a 
mean ± SD (range) 
0.247 ± 0.32 
(-0.18 – 1.05) 
0.87 ± 0.42 
(0.40 – 1.40) 
0.0050 b 
0.30 ± 0.36 
(-0.18 – 1.40) 
Preop. OCT findings    
Posterior staphyloma 4 3 0.0060 c 7 
Retinoschisis-like 
thickening 
3 3 0.0030 c 6 
a LogMAR BCVA at 6 months after the last surgery; b Mann Whitney U-test; c Fisher’s exact test.  
"disc vein diameter" = width (~ 150 um) of the vein on the edge of the optic disc; LogMAR BCVA 
= logarithm of the minimal angle of resolution for best-corrected visual acuity;  OCT = optical 
coherence tomography; Preop. = preoperative; Postop. = postoperative; SD = standard 
deviation 
Tables




















(G1 + G2) 
Among  
3 Groups 
G1 vs. G2 G1 vs. G3 G2 vs. G3 
Axial length  ≥26.0 mm ≥26.0 mm < 26.00 mm      
 
≥30.0 mm <30.0 mm  
 
    
 
Number of patients 3 10 13 36     49 
Patient age, years 
mean ± 1 SD (range) 
63.3 ± 6.1 
(58 – 70) 
54.2 ± 9.4  
(34 – 70) 
56.0 ± 9.4 
(34 – 70) 
66.4 ± 6.2 
(56 – 82) 
<0.0001 c 0.232 e 0.800 e 0.002 e 
63.4± 8.60 
(34 – 82) 
Men/ Women 0/3 3/7 3/10 15/21 0.40 d    18/31 
Number of eyes 3 12 15 37     52 




II 0 4 4 9 0.66 d    13 
III 1 4 5 18     23 




(1 – 24) 
3.3±2.2 
(0.75 – 6) 
4.8±6.1 
(1 – 24) 
3.0±2.8 
(0.5 – 12) 
0.60 c    
3.5±4.0 
(0.5 – 24) 
Preoperative          
Axial length, mm 
mean ± SD (range) 
31.0 ± 0.9 
(30.1 – 
31.9) 
27.0 ± 0.7 
(26.0 – 
28.1) 
27.8 ± 1.8 
(26.0 – 
31.9) 
23.4 ± 1.1 
(21.1 – 
25.7) 






-7.9 ± 9.2 
(-18.5 – 
-2.5 ) 
-9.6 ± 3.9 
(-17.4 – 
-3.8 ) 
-9.3 ± 5.0 
(-18.5 – 
-2.5) 
-0.4 ± 2.3 
(-5.5 – 4.4) 
<0.0001 c 0.99 e 0.54 e <0.0001 e 
-3.0 ± 5.2 
(-18.5 – 4.4) 
  
Size of hole, relative 
to "disc vein 
diameter" 
5.8 ± 1.4 
(4.7 – 7.4) 
4.6 ± 2.7 
(1.5 – 9.7) 
4.9 ± 2.4 
(1.5 – 9.7) 
3.9 ± 1.3 
(1.2 – 6.7) 
0.14 c    
4.1 ± 1.6 
(1.2 – 9.7) 
Preop. LogMAR 
BCVA 
mean ± SD (range) 
0.77 ± 0.35 
(0.40 – 
1.10) 
0.70 ± 0.44 
(0.10 – 
1.40) 
0.71 ± 0.42 
(0.10 – 
1.40) 
0.59 ± 0.30 
(0.05 – 
1.05) 
0.54 c    
0.62 ± 0.34 
(0.05 – 
1.40) 
Posterior staphyloma 3 3 6 1 <0.0001 d 0.070 d 0.0004 d 0.028 d 7 
Retinoschisis-like 
thickening present 
2 2 4 2 0.01 d 0.15 d 0.02 d 0.25 d 6 
Postoperative          
Hole 
closure 
Initial 0 (0%) 11 (91.7%) 11 (73.3%) 37 (100%) <0.0001 d <0.0001 d <0.0001 d 0.24 d 48 (92.3%) 
Final 0 (0%) 11 (91.7%) 11 (73.3%) 37 (100%) <0.0001 d <0.0001 d <0.0001 d 0.24 d 48 (92.3%) 
Postop. LogMAR 
BCVA a 
mean ± SD (range) 
0.93 ± 0.50 
(0.40 – 
1.40) 
0.33 ± 0.31 
(0.05 – 
1.00) 
0.45 ± 0.30 
(0.05–1.40) 
0.23 ± 0.32 
(-0.18 – 
1.05) 
0.042 c 0.34 e 0.27 e 0.75 e 
0.30 ± 0.36 
(-0.18 – 
1.40) 
Change in LogMAR 
BCVA 
mean ± SD (range) 
0.16 ± 0.15 
(0 – 0.3) 
-0.39 ± 0.42 
(-1.24 – 0) 
-0.26 ± 0.43 
(-1.24 to 
0.30) 
-0.36 ± 0.32 
(-1.0 – 0.22) 
0.036 c 0.015 e 0.020 e 1.00 e 
-0.33 ± 0.36 
(-1.24 – 
0.30) 
a LogMAR BCVA at 6 months after the last surgery 
b Comparison was made among 3 groups 
G1 = Group 1 (severely high myopia); G2 = Group 2 = moderately high myopia; G3 = Group 3 = emmetropia/mild myopia/hyperopia 
c Kruskal Wallis H-test; d Fisher’s exact test; e Dunnett’s rank test 
"disc vein diameter" = width (~ 150 um) of the vein on the edge of the optic disc; LogMAR BCVA = logarithm of the minimal angle of resolution 
for best-corrected visual acuity; Preop. = preoperative; Postop. = postoperative; SD = standard deviation 





















1 58 F 4 L 31.9 5 1 1 1 
2 62 F 4 R 31.2 1 1 0 1 
3 70 F 3 R 30.1 24 1 1 0 
4 62 F 3 R 26.7 NA 0 1 1 
Mean or (%) 63 0/4 (0)  1/4 (25) 30.0  3/4 (75) 3/4 (75) 3/4 (75) 
Initial Success 
5 34 F 4 L 28.1 6 0 0 0 
6 63 F 3 R 28.1 6 1 1 1 
7 43 F 4 L 28.1 5 0 0 0 
8 50 M 4 L 27.2 1 0 0 0 
9 49 M 2 R 27.2 0.75 1 0 0 
10 58 M 3 L 26.9 1 0 0 0 
11 53 F 4 R 26.7 2 0 0 0 
12 62 F 3 L 26.5 NA 0 0 0 
13 66 F 2 L 26.3 3 0 0 0 
14 59 M 2 R 26.2 2 1 0 0 
15 51 F 2 R 26 6 0 0 0 
Mean or (%) 53.5 4/11 (36.4)  6/11 (54.5) 27.0  3/11 (27.3)* 1/11 (9.1)* 1/11 (9.1)* 
P value 0.030* 1.0† 0.36† 0.57† 0.056* 0.57* 0.24† 0.033† 0.033† 
 
* Mann Whitney U-test; †Fisher’s exact test 
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